logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 20 of 27 Items
Showing 1 - 20 of 27 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article
|
Research

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY,  et al.
2024-05-09 • Nature Communications
2024-05-09 • Nature Communications
Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...
Journal Article
|
Research

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article
|
Research

Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up

Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M,  et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
BACKGROUND
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...
Journal Article
|
Short Report

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y,  et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...
Journal Article
|
Research

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD,  et al.
2024-01-20 • medRxiv
2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Journal Article
|
Protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|
Research

Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis

Trevisi L, Hernán MA, Mitnick CD, Khan UT, Seung KJ,  et al.
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Journal Article
|
Research

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Rich ML, Khan UT, Zeng C, LaHood AN, Franke MF,  et al.
2023-06-01 • International Journal of Tuberculosis and Lung Disease
2023-06-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

OB...
Journal Article
|
Research

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective

Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M,  et al.
2023-04-28 • PLOS Global Public Health
2023-04-28 • PLOS Global Public Health
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...
Journal Article
|
Research

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|
Research

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Journal Article
|
Research

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S,  et al.
2022-09-15 • Clinical Infectious Diseases
2022-09-15 • Clinical Infectious Diseases
RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...
Journal Article
|
Short Report

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Journal Article
|
Letter

Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations

Varaine FFV, Guglielmetti L, Huerga H, Bonnet MMB, Kiria N,  et al.
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Journal Article
|
Research

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

Franke MF, Khan P, Hewison C, Khan U, Huerga H,  et al.
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...
Journal Article
|
Commentary

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S,  et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...
Journal Article
|
Protocol

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Protocol
|
Research Protocol

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Khan UT, Huerga H, Khan AS, Mitnick CD, Hewison CCH,  et al.
2019-08-20 • BMC Infectious Diseases
2019-08-20 • BMC Infectious Diseases
BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...